On May 1, 2020, Pulse Biosciences, Inc. (the “Company”) issued a press release announcing to holders of shares of its common stock that the Company has set the record date and pricing structure for its previously-announced rights offering.

A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Pulse Biosciences, Inc. Exhibit
EX-99.1 2 nt10010624x9_ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 Pulse Biosciences,…
To view the full exhibit click here

About Pulse Biosciences, Inc. (NASDAQ:PLSE)

Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. NPES provides treatment in a range of dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret’s esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing a system for the delivery of NPES treatments, identified as the PulseTx system (PulseTx). The PulseTx system delivers NPES pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.